Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.00%
#3 Cysic Cysic +7.96%
#4 Palladium Network Palladium Network +7.69%
#5 Orochi Network Orochi Network +3.33%
#6 Fartcoin Fartcoin +3.18%
#7 DOVU DOVU +2.80%
#8 Wormhole Bridged Wrapped SOL (Sui) Wormhole Bridged Wrapped SOL (Sui) +2.65%
#9 Akedo Akedo +2.55%
#10 KOTAI KOTAI +2.34%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Kedudukan dalam Saham #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Harga Saham
$0.00162013
Disegerakkan terakhir: 2025-01-03
Modal Pasaran
$156.25K
Perubahan (1 hari)
0.36%
Perubahan (1 tahun)
0.00%
Negara
SE
Perdagangan Cyxone AB (publ) (CYXO)

Kategori

Healthcare
Pendapatan untuk Cyxone AB (publ) (CYXO)
Pendapatan pada Jun 2024 TTM: $-2.04M
Menurut laporan kewangan terkini Cyxone AB (publ), pendapatan semasa syarikat ialah $-2.04M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-4.07M, peningkatan berbanding pendapatan pada tahun 2021 yang berjumlah $-4.98M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Cyxone AB (publ) dari 2015 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-2.04M -10.32%
2023 $-2.28M -44.05%
2022 $-4.07M -18.14%
2021 $-4.98M -16.09%
2020 $-5.93M 57.40%
2019 $-3.77M 118.05%
2018 $-1.73M 60.09%
2017 $-1.08M 135.58%
2016 $-458.07K -2,484.88%
2015 $19.21K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -258,252.37%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -95,564.36%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -147,199.10%
BE